– USA, MA – TESARO, Inc. (Nasdaq:TSRO), an oncology-focused biopharmaceutical company, today announced the nomination of Garry A. Nicholson for election to the Company’s Board of Directors. He will stand for election as an independent director at TESARO’s 2015 annual meeting of stockholders, which is scheduled for May 14, 2015.
Mr. Nicholson brings 20 years of experience in oncology drug development and commercialization. He most recently served as President, Pfizer Oncology, from May 2008 until March 2015. As the first leader of Pfizer’s global, dedicated oncology business, Mr. Nicholson had direct responsibility for business strategy and operations, including the oncology sales and marketing organizations globally, clinical development for both early and late stage pipeline candidates, and for licensing and acquisitions.
“Garry is a highly accomplished leader in the biopharmaceutical industry with deep expertise in oncology product commercialization and development, and his experience will be a valuable asset to TESARO,” said Lonnie Moulder, CEO of TESARO. “I look forward to working with Garry upon his election as the Company continues to grow, prepare for its first potential product launch and advance its pipeline of product candidates.”
Prior to joining Pfizer, Mr. Nicholson worked at Eli Lilly and Company in a number of leadership roles, including sales management, marketing, human resources, sales and marketing, and oncology drug development. Mr. Nicholson earned a bachelor of science degree in pharmacy from the University of North Carolina, Chapel Hill, and a master of business administration degree from the University of South Carolina, Columbia.
TESARO is an oncology-focused biopharmaceutical company dedicated to improving the lives of cancer patients by acquiring, developing and commercializing safer and more effective therapeutics.
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
Comments are closed.